Pfizer Initiates Ph III Trials for Invasive Pneumococcal Disease and Pneumonia Vaccine

Pfizer Initiates Ph III Trials for Invasive Pneumococcal Disease and Pneumonia Vaccine

Source: 
CP Wire
snippet: 

Pfizer Inc. (NYSE:PFE) announced today the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, for the prevention of invasive disease and pneumonia caused by  Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older.